The Multi-Target Drug M30 Shows Pro-Cognitive and Anti-Inflammatory Effects in a Rat Model of Alzheimer's Disease

Journal of Alzheimer's Disease

Volumn 47, Issue 2, 2015, Pages 373-383

  Pimentel, Luisa S ^a   Allard, Simon ^a   Do Carmo, Sonia ^a   Weinreb, Orly ^b   Danik, Marc ^a   Hanzel, Cecilia E ^a   Youdim, Moussa B ^b   Cuello, A Claudio ^a  

^a MCGILL UNIVERSITY   (Canada)

^b Abital Pharma Pipeline Ltd   (Israel)

Author keywords

Alzheimer's disease; CNS inflammation; cognitive impairments; neurodegeneration; neuroprotection; transgenic rat

Indexed keywords

AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG; [5 (N METHYL N PROPARGYLAMINOMETHYL) 8 HYDROXYQUINOLINE]; 5-(N-METHYL-N-PROPARGYLAMINOMETHYL)-8-HYDROXYQUINOLINE; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; QUINOLINOL DERIVATIVE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COGNITION ASSESSMENT; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; MALE; NON-SPATIAL MEMORY TEST; NONHUMAN; NOVEL OBJECT LOCATION TEST; NOVEL OBJECT RECOGNITION TEST; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; TRANSGENIC RAT; ANIMAL; BRAIN; COGNITION; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; LIPID PEROXIDATION; METABOLISM; MICROGLIA; PATHOLOGY; PHYSIOLOGY; RECOGNITION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN; COGNITION; DISEASE MODELS, ANIMAL; FEMALE; HYDROXYQUINOLINES; LIPID PEROXIDATION; MALE; MICROGLIA; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; RATS, TRANSGENIC; RECOGNITION (PSYCHOLOGY);

EID: 84938689993     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-143126     Document Type: Article

References (39)

1. Gal S, Zheng H, Fridkin M, Youdim MBH (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem 95, 79-88.
2. Avramovich-Tirosh Y, Reznichenko L, Mit T, Zheng H, Fridkin M, Weinreb O, Mandel S, Youdim MBH (2007) Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron-chelating-antioxidants, M-30 and green tea polyphenol, EGCG. Curr Alzheimer Res 4, 403-411.
3. Kupershmidt L, Weinreb O, Amit T, Mandel S, Carri MT, Youdim MBH (2009) Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motorneuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J 23, 3766-3779.
4. Kupershmidt L, Amit T, Bar-Am O, Youdim MBH, Weinreb O (2012) The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease. Antioxid Redox Signal 17, 860-877.
5. Zheng H, Gal S, Weiner LM, Bar-Am O, Warshawsky A, Fridkin M, Youdim MBH (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: In vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 95, 68-78.
6. Zhu W, Xie W, Pan T, Xu P, Fridkin M, Zheng H, Jankovic J, Youdim MBH, Le W (2007) Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J 21, 3835-3844.
7. Leon WC, Canneva F, Partridge V, Allard S, Ferretti MT, DeWilde A, Vercauteren F, Atifeh R, Ducatenzeiler A, Klein W, Szyf M, Alhonen L, Cuello AC (2010) A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. J Alzheimers Dis 20, 113-126.
8. Zheng H, Weiner LM, Bar-Am O, Epsztejn S, Cabantchik ZI, WarshawskyA, YoudimMBH, FridkinM(2005) Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem 13, 773-783.
9. Allard S, Leon WC, Pakavathkumar P, Bruno MA, Ribeiroda-Silva A, Cuello AC (2012) Impact of the NGF maturation and degradation pathway on the cortical cholinergic system phenotype. J Neurosci 32, 2002-2012.
10. Hanzel CE, Pichet-Binette A, Pimentel LSB, IulitaMF, Allard S, Ducatenzeiler A, Do Carmo S, Cuello AC (2014) Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease. Neurobiol Aging 35, 2249-2262.
11. Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314-1318.
12. Olah M, Biber K, Vinet J, Boddeke HWGM(2011) Microglia phenotype diversity. CNS Neurol Disord Drug Targets 10, 108-118.
13. Karperien A, Ahammer H, Jelinek HF (2013) Quantitating the subtleties of microglial morphology with fractal analysis. Front Cell Neurosci 7, 3.
14. Jack CR, Holtzman DM (2013) Biomarker modeling of Alzheimer's disease. Neuron 80, 1347-1358.
15. Jack CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain 132, 1355-1365.
16. Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, BucklesV, OliverA, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367, 795-804.
17. Maruyama W, Akao Y, Youdim MB, Naoi M (2000) Neurotoxins induce apoptosis in dopamine neurons: Protection by N-propargylamine-1(R)-and (S)-aminoindan, rasagiline and TV1022. J Neural Transm Suppl, 171-186.
18. Akao Y, Maruyama W, Shimizu S, Yi H, Nakagawa Y, Shamoto-Nagai M, Youdim MBH, Tsujimoto Y, Naoi M (2002) Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, Npropargyl-1(R)-aminoindan. J Neurochem 82, 913-923.
19. Youdim MB (2003) Rasagiline: An anti-Parkinson drug with neuroprotective activity. Expert Rev Neurother 3, 737-749.
20. Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O, Youdim MBH (2004) Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J 18, 1471-1473.
21. Gal S, Zheng H, Fridkin M, YoudimMBH(2010) Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelatormonoamine oxidase inhibitor drug, M30. Neurotox Res 17, 15-27.
22. Zheng H, Amit T, Bar-Am O, Fridkin M, Youdim MBH, Mandel SA (2012) From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease. J Alzheimers Dis 30, 1-16.
23. YoudimMBH, Fridkin M, ZhengH(2004) Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases. J Neural Transm 111, 1455-1471.
24. Ferretti MT, Partridge V, Leon WC, Canneva F, Allard S, Arvanitis DN, Vercauteren F, Houle D, Ducatenzeiler A, Klein WL, Glabe CG, Szyf M, CuelloAC(2011) Transgenic mice as a model of pre-clinical Alzheimer's disease. Curr Alzheimer Res 8, 4-23.
25. Ferretti M, Allard S, Partridge V, Ducatenzeiler A, Cuello AC (2012) Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology. J Neuroinflammation 9, 62.
26. Butler MP, O'Connor JJ, Moynagh PN (2004) Dissection of tumor-necrosis factor-alpha inhibition of long-term potentiation (LTP) reveals a p38 mitogen-activated protein kinase-dependent mechanism which maps to early-but not late-phase LTP. Neuroscience 124, 319-326.
27. Lourenco MV, Clarke JR, Frozza RL, Bomfim TR, Forny-Germano L, Batista AF, Sathler LB, Brito-Moreira J, Amaral OB, Silva CA, Freitas-Correa L, Espírito-Santo S, Campello-Costa P, Houzel J-C, Klein WL, Holscher C, Carvalheira JB, Silva AM, Velloso LA, Munoz DP, Ferreira ST, De Felice FG (2013) TNF-mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's-amyloid oligomers in mice and monkeys. Cell Metab 18, 831-843.
28. Tarkowski E, Liljeroth AM, Minthon L, Tarkowski A, Wallin A, Blennow K (2003) Cerebral pattern of pro-and antiinflammatory cytokines in dementias. Brain Res Bull 61, 255-260.
29. Tobinick E (2009) Tumour necrosis factor modulation for treatment of Alzheimer's disease: Rationale and current evidence. CNS Drugs 23, 713-725.
30. Hattori A, Tanaka E, Murase K, Ishida N, Chatani Y, Tsujimoto M, Hayashi K, Kohno M (1993) Tumor necrosis factor stimulates the synthesis and secretion of biologically active nerve growth factor in non-neuronal cells. J Biol Chem 268, 2577-2582.
31. Montgomery SL, Mastrangelo MA, Habib D, Narrow WC, Knowlden SA, Wright TW, Bowers WJ (2011) Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology: Implications for chronic pan-TNF-suppressive therapeutic strategies in the brain. Am J Pathol 179, 2053-2070.
32. Trudler D, Weinreb O, Mandel SA, Youdim MB, Frenkel D (2014) DJ-1 deficiency triggers microglia sensitivity to dopamine toward a pro-inflammatory phenotype that is attenuated by rasagiline. J Neurochem 129, 434-447.
33. Kupershmidt L, Amit T, Bar-Am O, Youdim MBH, Weinreb O (2012) Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice. Mech Ageing Dev 133, 267-274.
34. Seabrook TJ, Jiang L, Maier M, Lemere CA (2006) Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia 53, 776-782.
35. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101-112.
36. WalshDM, Selkoe DJ (2004) Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44, 181-193.
37. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539.
38. Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D (2009) Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62, 788-801.
39. Maarouf CL, Daugs ID, Kokjohn TA, Walker DG, Hunter JM, Kruchowsky JC, Woltjer R, Kaye J, Castaño EM, Sabbagh MN, Beach TG, Roher AE (2011) Alzheimer's disease and non-demented high pathology control nonagenarians: Comparing and contrasting the biochemistry of cognitively successful aging. PLoS One 6, e27291.